HOME >> BIOLOGY >> NEWS
Gene involved in common birth defect also regulates skin biology

Following up on an earlier discovery that a gene called IRF6 is involved in the common birth defect cleft lip and palate, researchers at the University of Iowa Roy J. and Lucille A. Carver College of Medicine and their colleagues have identified the function of the gene. Their latest findings, published online Oct. 15 in Nature Genetics, reveal an unexpected role for IRF6 in the growth and development of skin cells, a discovery that may have implications for wound healing and cancer research.

In 2002, Brian Schutte, Ph.D., UI associate professor of pediatrics and nursing, and Jeff Murray, M.D., UI professor of pediatrics, pediatric dentistry and biological sciences, and the Roy J. Carver Chair in Perinatal Health, led a study showing that mutations in IRF6 cause Van der Woude syndrome (VWS), a rare, dominantly inherited form of cleft lip and palate. Subsequently, the researchers found that this gene also is mutated in 10 to 15 percent of the more common, so-called non-syndromic cases of cleft lip and palate. Cleft lip and palate, where the lip or both the lip and palate (roof of the mouth) fail to close, occurs in approximately one of every 1,000 babies.

In order to determine the function of this gene, the researchers created mice that lacked IRF6. These mice had very abnormal skin as well as a cleft palate. Detailed analysis of the mice revealed that IRF6 regulates the proliferation and differentiation of keratinocytes -- the main cell type in the epidermis or outer layer of skin. Keratinocytes also provide a protective barrier around the mouth, gut, liver, lung, kidney and other internal organs.

"This study really looks at the role of IRF6 in skin development. By focusing on skin we felt we could learn more about this specific cell type that is also abnormal in the palate," Schutte said. "The insight we gained into the function of IRF6 will help focus research efforts to identify other genes involved in cleft lip and palate."

<
'"/>

Contact: Dave Pedersen
david-pedersen@uiowa.edu
319-335-8032
University of Iowa
15-Oct-2006


Page: 1 2 3

Related biology news :

1. U-M researchers identify gene involved in breast cancer
2. Identified main genetic variants involved in response to HIV
3. Oregon researchers involved in new Clovis-age impact theory
4. LSU professor involved in genome sequencing of the first marsupial
5. Diseased brain cells more involved in ALS-associated motor neuron death
6. Researchers identify gene involved in dog size
7. UCLA identifies new molecule involved in the bodys processing of dietary fat
8. Gene controlling circadian rhythms may be involved in onset of bipolar disorder
9. Mechanisms involved with tumor relapse identified
10. Scientists find genes involved in the battle between Hessian flies and wheat
11. UCR involved in discovery of diabetes fighting molecule

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene involved common birth defect also regulates skin biology

(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: